25 Aug 2020 Governance
Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK
After eight successful years with us, Angela Smith-Morgan will be stepping down from her role as Co CEO of Leukaemia UK on 3rd September.
Angela was responsible for driving through the merger with Leuka in November 2019, and is now leaving the charity in a strong position to build on the remarkable transformation she engineered.
She has been a valued Co CEO of the merged charity and a visionary sole CEO of the original charity. We thank her for her outstanding work on our behalf and wish her the very best in the future.
Related posts
7 November 2024
University of Southampton’s Dr Giorgia Chiodin Wins Olive Boles Innovation Award
Dr Giorgia Chiodin from the University of Southampton has been awarded the prestigious Olive Boles Innovation Award for 2024. Awarded annually to a Leukaemia UK John Goldman Fellow, this award…
4 September 2022
Worrying numbers of leukaemia patients are being misdiagnosed or waiting too long for a blood test, say leading UK leukaemia charities
Patients in the UK face “the luck of the draw” when presenting with leukaemia symptoms. GPs are often left without adequate support to provide blood tests or process the results…
30 January 2024
Leukaemia UK bolsters research and advocacy team, in support of ambitious strategy to accelerate progress in the diagnosis, treatment, and care of leukaemia
Leukaemia UK is pleased to announce Dr Simon Ridley as the new Director of Research and Advocacy and Dr Georgia Papacleovoulou as the organisation’s first ever Head of Policy and…
10 November 2021
An urgent call from One Cancer Voice group of cancer charities for the Comprehensive Spending Review to deliver Government commitments to improve cancer survival & care
Leukaemia UK has joined with 50 other cancer charities in writing to the Prime Minister, Chancellor of the Exchequer and Secretary of State for Health and Social Care. We are calling on the Government to urgently deliver on commitments to improve cancer survival and care in the forthcoming Spending Review.